Methodologies and clinical utility of ADAMTS-13 activity testing

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 1, 2010, Pages 82-90

  Just, Sarah ^a  

^a Central Queensland Pathology Laboratory   (Australia)

Author keywords

ADAMTS 13 assays; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT VON WILLEBRAND FACTOR 73; RECOMBINANT VON WILLEBRAND FACTOR A2; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AGAR GEL ELECTROPHORESIS; BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; COLLAGEN BINDING ASSAY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRETS ASSAY; HEART DISEASE; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; LIVER CIRRHOSIS; MONITORING; ORGAN TRANSPLANTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREGNANCY; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; RISTOCETIN INDUCED AGGREGATION ASSAY; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; WESTERN BLOTTING;

ADAM PROTEINS; COLLAGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PLATELET AGGREGATION; PROTEIN BINDING; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISTOCETIN; THROMBOTIC MICROANGIOPATHIES; VON WILLEBRAND FACTOR;

EID: 77951034070     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1248727     Document Type: Review

References (57)

1. Moschowitz E. Hyalin thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924 24 21-24
2. Furlan M, Robles R, Lmmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996 87 (10) 4223-4234 (Pubitemid 26152266)
3. Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996 87 (10) 4235-4244
4. Levy G G., Nichols W C., Lian E C. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001 413 (6855) 488-494 (Pubitemid 32938741)
5. Tsai H M., Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 (22) 1585-1594 (Pubitemid 28536133)
6. Favaloro E J. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 (8) 727-744
7. Gerritsen H E., Turecek P L., Schwarz H P., Lmmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999 82 (5) 1386-1389 (Pubitemid 29527624)
8. Zheng X L., Kaufman R M., Goodnough L T., Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004 103 (11) 4043-4049
9. Zheng X, Pallera A M., Goodnough L T., Sadler J E., Blinder M A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003 138 (2) 105-108 (Pubitemid 36222497)
10. Rick M E., Moll S, Taylor M A., Krizek D M., White G C. II, Aronson D L. Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2002 88 (4) 598-604 (Pubitemid 35174001)
11. Mannucci P M., Canciani M T., Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001 98 (9) 2730-2735
12. Bhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002 81 (8) 430-435 (Pubitemid 36067656)
13. Bhm M, Sharrer I. Determination of ADAMTS-13 activity based on VWF:RCo measurements with the BC von Willebrand reagent. Dade Behring J Winter 2005/2006 22-26
14. Dong J F., Moake J L., Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002 100 (12) 4033-4039 (Pubitemid 35396870)
15. Shenkman B, Inbal A, Tamarin I, Lubetsky A, Savion N, Varon D. Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition. Br J Haematol 2003 120 (4) 597-604 (Pubitemid 36255859)
16. Cruz M A., Whitelock J, Dong J F. Evaluation of ADAMTS-13 activity in plasma using recombinant von Willebrand Factor A2 domain polypeptide as substrate. Thromb Haemost 2003 90 (6) 1204-1209 (Pubitemid 38004445)
17. Kokame K, Matsumoto M, Fujimura Y, Miyata T. VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 2004 103 (2) 607-612 (Pubitemid 38140094)
18. Whitelock J L., Nolasco L, Bernardo A, Moake J, Dong J F., Cruz M A. ADAMTS-13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF-A2 domain as substrate. J Thromb Haemost 2004 2 (3) 485-491 (Pubitemid 40185662)
19. Zhou W, Tsai H M. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost 2004 91 806-811 (Pubitemid 38477463)
20. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006 46 (8) 1444-1452 (Pubitemid 44117975)
21. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005 129 (1) 93-100 (Pubitemid 40524057)
22. Groot E, Hulstein J J., Rison C N., de Groot P G., Fijnheer R. FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura. J Thromb Haemost 2006 4 (3) 698-699
23. Studt J D., Bhm M, Budde U, Girma J P., Varadi K, Lmmle B. Measurement of von Willebrand factor-cleaving protease (ADAMTS-13) activity in plasma: a multicenter comparison of different assay methods. J Thromb Haemost 2003 1 (9) 1882-1887
24. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, Girma J P. Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 1999 82 (5) 1382-1385
25. Kremer Hovinga J A., Mottini M, Lmmle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006 4 (5) 1146-1148
26. Shelat S G., Smith P, Ai J, Zheng X L. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost 2006 4 (8) 1707-1717
27. Tripodi A, Chantarangkul V, Bhm M et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004 2 (9) 1601-1609
28. Amar S, Rice L, Dong J-F et al. Evaluation of ADAMTS-13 von Willebrand factor cleaving protease activity using a rapid endothelial cell surface based assay in two chronic relapsing TTP patients receiving plasma infusion. Blood 2002 100 684a
29. Remuzzi G, Galbusera M, Noris M et al, Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002 100 (3) 778-785
30. Tripodi A, Peyvandi F, Chantarangkul V et al. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). J Thromb Haemost 2008 6 (9) 1534-1541
31. Adcock D M., Hoefner D M., Kottke-Marchant K, Marlar R A., Szamosi D I., Warunek D J. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline. 5th ed. CLSI Document H21A5. Wayne, PA Clinical Laboratory Standards Institute 2008
32. Tsai H M., Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 (22) 1585-1594
33. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 (22) 1578-1584 (Pubitemid 28536132)
34. Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001 98 (6) 1765-1772
35. Savasan S, Lee S K., Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 2003 101 (11) 4449-4451
36. Peyvandi F, Ferrari S, Lavoretano S, Canciani M T., Mannucci P M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004 127 (4) 433-439
37. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007 33 (8) 787-797
38. Bianchi V, Robles R, Alberio L, Furlan M, Lmmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002 100 (2) 710-713 (Pubitemid 34761143)
39. Peyvandi F, Siboni S M., Lambertenghi Deliliers D et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006 134 187-195
40. Hulstein J J., van Runnard Heimel P J., Franx A et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 2006 4 (12) 2569-2575
41. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci P M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003 88 (9) 1029-1034
42. Rossi F C., Angerami R N., de Paula E V. et al. A novel association of acquired ADAMTS13 inhibitor and acute dengue virus infection. Transfusion 2009 September 24 (Epub ahead of print)
43. Ohguchi H, Sugawara T, Harigae H. Thrombotic thrombocytopenic purpura complicated with hypereosinophilic syndrome. Intern Med 2009 48 (18) 1687-1690
44. Kappers-Klunne M C., van Asten J G., van Vliet H H. ADAMTS-13 and Von Willebrand factor in relation to platelet response during plasma exchange in thrombotic thrombocytopenic purpura: a clue for disease mechanism? Ann Hematol 2009 88 (10) 1025-1028
45. Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol 2006 136 649-655
46. Knovich M A., Craver K, Matulis M D., Lawson H, Owen J. Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma. Am J Hematol 2004 76 (3) 286-290
47. Peyvandi F, Lavoretano S, Palla R et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008 93 (2) 232-239
48. Reiter R A., Knbl P, Varadi K, Turecek P L. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 2003 101 (3) 946-948 (Pubitemid 36139364)
49. Feys H B., Canciani M T., Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007 138 (4) 534-540 (Pubitemid 47063038)
50. Moore J C., Hayward C PM, Warkentin T E., Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001 98 (6) 1842-1846
51. Uemura M, Fujimura Y, Matsuyama T et al. Potential role of ADAMTS13 in the progression of alcoholic hepatitis. Curr Drug Abuse Rev 2008 1 (2) 188-196
52. Uemura M, Fujimura Y, Matsumoto M et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008 99 (6) 1019-1029 (Pubitemid 351810483)
53. Gombos T, Mak V, Cervenak L et al. Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009 102 (3) 573-580
54. Vergouwen M D., Bakhtiari K, van Geloven N, Vermeulen M, Roos Y B., Meijers J C. Reduced ADAMTS13 activity in delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2009 29 (10) 1734-1741
55. Chion C K., Doggen C J., Crawley J T., Lane D A., Rosendaal F R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007 109 (5) 1998-2000
56. Crawley J T., Lane D A., Woodward M, Rumley A, Lowe G D. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008 6 (4) 583-588
57. de Mast Q, Groot E, Asih P B. et al. ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria. Am J Trop Med Hyg 2009 80 (3) 492-498